Results from nonclinical studies of Cidara’s lead candidate CD101 IV (formerly biafungin), a novel, long-acting echinocandin, will be presented this week at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington D.C. Four posters and one abstract regarding CD101 IV have been accepted for presentation. Kieren Marr, M.D., professor of medicine and oncology, and director of the transplant and oncology infectious diseases program at the Johns Hopkins University School of Medicine…
CidaraSeptember 9, 2014